By dissecting ZIKV action on GSCs, we provide an alternative tool for glioblastoma treatment, and demonstrate that mir34c can inhibit GSCs, such as ZIKV, by reducing Bcl2 that could potentially increase the effect of chemo/radiotherapies. This evidence concerns the gene BCL2 and glioblastoma.